Nuvalent, Inc.

NasdaqGS NUVL

Nuvalent, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Nuvalent, Inc. EBITDA Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqGS: NUVL

Nuvalent, Inc.

CEO	Dr. James R. Porter Ph.D.
IPO Date	July 29, 2021
Location	United States
Headquarters	One Broadway
Employees	127
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals

Description

Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years